Cerebello-spinal TDCS in Ataxia: A Randomized, Double-blind, Sham-controlled, Crossover Trial
Authors
Affiliations
Objective: To investigate whether a 2-week treatment with cerebellar anodal and spinal cathodal transcranial direct current stimulation (tDCS) could reduce symptoms in patients with neurodegenerative ataxia and could modulate cerebello-motor connectivity at the short and long terms.
Methods: We performed a double-blind, randomized, sham-controlled, crossover trial with cerebello-spinal tDCS (5 d/wk for 2 weeks) in 20 patients with neurodegenerative ataxia. Each patient underwent a clinical evaluation before and after real tDCS or sham stimulation. A follow-up evaluation was performed at 1 and 3 months with a crossover washout period of 3 months. Cerebello-motor connectivity was evaluated with transcranial magnetic stimulation at baseline and at each follow-up.
Results: Cerebello-spinal tDCS showed a significant improvement in all performance scores (Scale for the Assessment and Rating of Ataxia, International Cooperative Ataxia Rating Scale, 9-Hole Peg Test, 8-m walking time), in motor cortex excitability, and in cerebellar brain inhibition compared to sham stimulation.
Conclusions: A 2-week treatment with cerebello-spinal tDCS reduces symptoms in patients with ataxia and restores motor cortex inhibition exerted by cerebellar structures. Cerebello-spinal tDCS might represent a promising future therapeutic and rehabilitative approach in patients with neurodegenerative ataxia, still an orphan disorder of any pharmacologic intervention.
Clinical Trial Registration: NCT03120013.
Classification Of Evidence: This study provides Class II evidence that cerebello-spinal stimulation is effective and safe in cerebellar ataxia.
Reumers S, Maas R, Schutter D, Teerenstra S, Kessels R, de Leeuw F Mov Disord. 2024; 40(1):121-131.
PMID: 39487643 PMC: 11752977. DOI: 10.1002/mds.30043.
Matsugi A, Ohtsuka H, Bando K, Kondo Y, Kikuchi Y Mov Disord Clin Pract. 2024; 11(11):1323-1334.
PMID: 39221650 PMC: 11542298. DOI: 10.1002/mdc3.14205.
Hamdan A, Hooker A, Chen X, Traschutz A, Schule R, Synofzik M CPT Pharmacometrics Syst Pharmacol. 2024; 13(8):1327-1340.
PMID: 38769902 PMC: 11330187. DOI: 10.1002/psp4.13162.
Potashman M, Rudell K, Pavisic I, Suminski N, Doma R, Heinrich M Cerebellum. 2024; 23(5):2012-2027.
PMID: 38713312 PMC: 11489265. DOI: 10.1007/s12311-024-01700-2.
Brito R, Fabricio J, Araujo A, Barreto G, Baltar A, Monte-Silva K Cerebellum. 2024; 23(5):1993-2002.
PMID: 38693314 DOI: 10.1007/s12311-024-01696-9.